[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Kaide et al., 2020 - Google Patents

Identification and evaluation of bisquinoline scaffold as a new candidate for α-synuclein-PET imaging

Kaide et al., 2020

Document ID
12948739554662678409
Author
Kaide S
Watanabe H
Shimizu Y
Iikuni S
Nakamoto Y
Hasegawa M
Itoh K
Ono M
Publication year
Publication venue
ACS Chemical Neuroscience

External Links

Snippet

α-Synuclein (α-syn) aggregates are pathologically associated with the hallmarks found in brains affected by synucleinopathies such as Parkinson's disease (PD) and multiple system atrophy (MSA). Therefore, the in vivo detection of α-syn aggregates using radiolabeled …
Continue reading at pubs.acs.org (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Similar Documents

Publication Publication Date Title
Kaide et al. Identification and evaluation of bisquinoline scaffold as a new candidate for α-synuclein-PET imaging
Chu et al. Design, synthesis, and characterization of 3-(benzylidene) indolin-2-one derivatives as ligands for α-synuclein fibrils
Li et al. Synthesis and in vivo evaluation of a novel PET radiotracer for imaging of synaptic vesicle glycoprotein 2A (SV2A) in nonhuman primates
Okamura et al. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease
Ariza et al. Tau positron emission tomography (PET) imaging: past, present, and future
Gobbi et al. Identification of three novel radiotracers for imaging aggregated tau in Alzheimer’s disease with positron emission tomography
Verdurand et al. In silico, in vitro, and in vivo evaluation of new candidates for α-synuclein PET imaging
Wang et al. A facile radiolabeling of [18F] FDPA via spirocyclic iodonium ylides: preliminary PET imaging studies in preclinical models of neuroinflammation
Hsieh et al. Chalcones and five-membered heterocyclic isosteres bind to alpha synuclein fibrils in vitro
Matsumura et al. Structure–activity relationship study of heterocyclic phenylethenyl and pyridinylethenyl derivatives as tau-imaging agents that selectively detect neurofibrillary tangles in Alzheimer’s disease brains
Fujinaga et al. Synthesis and evaluation of novel radioligands for positron emission tomography imaging of metabotropic glutamate receptor subtype 1 (mGluR1) in rodent brain
Cai et al. Synthesis and preclinical evaluation of an 18F-labeled synaptic vesicle glycoprotein 2A PET imaging probe:[18F] SynVesT-2
Kaide et al. Chalcone analogue as new candidate for selective detection of α-synuclein pathology
Declercq et al. Comparison of new tau PET-tracer candidates with [18F] T808 and [18F] T807
Lindberg et al. Radiosynthesis, in vitro and in vivo evaluation of [18F] CBD-2115 as a first-in-class radiotracer for imaging 4R-tauopathies
Cary et al. Synthesis and evaluation of [18F] RAGER: a first generation small-molecule PET radioligand targeting the receptor for advanced glycation endproducts
Fujinaga et al. Development of N-[4-[6-(isopropylamino) pyrimidin-4-yl]-1, 3-thiazol-2-yl]-N-methyl-4-[11C] methylbenzamide for positron emission tomography imaging of metabotropic glutamate 1 receptor in monkey brain
Zhou et al. Synthesis and evaluation of fluorine-18 labeled 2-phenylquinoxaline derivatives as potential tau imaging agents
Cai et al. Candidate PET radioligand development for neurofibrillary tangles: two distinct radioligand binding sites identified in postmortem Alzheimer’s disease brain
Zhang et al. Synthesis and preliminary studies of a novel negative allosteric modulator, 7-((2, 5-dioxopyrrolidin-1-yl) methyl)-4-(2-fluoro-4-[11C] methoxyphenyl) quinoline-2-carboxamide, for imaging of metabotropic glutamate receptor 2
Fujinaga et al. Development of a 18F-labeled radiotracer with improved brain kinetics for positron emission tomography imaging of translocator protein (18 kDa) in ischemic brain and glioma
Oi et al. Synthesis and evaluation of novel radioligands for positron emission tomography imaging of the orexin-2 receptor
Li et al. Fluorine-18-Labeled Diaryl-Azines as Improved β-Amyloid Imaging Tracers: From Bench to First-in-Human Studies
Diner et al. Generation of clickable Pittsburgh Compound B for the detection and capture of β-Amyloid in Alzheimer’s Disease Brain
Kroth et al. PI-2620 lead optimization highlights the importance of off-target assays to develop a pet tracer for the detection of pathological aggregated tau in Alzheimer’s disease and other tauopathies